2,279 Shares in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Purchased by Caliber Wealth Management LLC KS

Key Points

• Caliber Wealth Management LLC KS purchased 2,279 shares of Jazz Pharmaceuticals, totaling approximately $283,000, marking an increasing interest from institutional investors in the company.
• Jazz Pharmaceuticals reported a miss on earnings with a Q1 EPS of $1.68, significantly below the consensus estimate of $4.65, alongside a revenue drop of 0.5% year-over-year.
• Despite the recent earnings setback, analysts have a consensus rating of "Moderate Buy" for Jazz Pharmaceuticals, with an average price target of $181.64, indicating potential upside in the stock's value.

Caliber Wealth Management LLC KS acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,279 shares of the specialty pharmaceutical company's stock, valued at approximately $283,000.

Other large investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its position in shares of Jazz Pharmaceuticals by 9.4% during the 1st quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company's stock valued at $131,000 after acquiring an additional 91 shares during the last quarter. Bessemer Group Inc. raised its holdings in shares of Jazz Pharmaceuticals by 0.3% during the fourth quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company's stock worth $3,317,000 after acquiring an additional 92 shares during the period. Kendall Capital Management raised its holdings in shares of Jazz Pharmaceuticals by 1.2% during the first quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company's stock worth $989,000 after acquiring an additional 95 shares during the period. Synovus Financial Corp grew its position in Jazz Pharmaceuticals by 0.5% in the fourth quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company's stock valued at $2,365,000 after purchasing an additional 100 shares in the last quarter. Finally, Quarry LP grew its position in Jazz Pharmaceuticals by 6.3% in the fourth quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company's stock valued at $209,000 after purchasing an additional 100 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Trading Down 0.3%

NASDAQ:JAZZ traded down $0.34 during midday trading on Wednesday, hitting $116.26. 80,687 shares of the company traded hands, compared to its average volume of 960,016. The firm's fifty day moving average is $110.48 and its 200-day moving average is $118.01. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The firm has a market capitalization of $7.04 billion, a P/E ratio of 15.55, a P/E/G ratio of 5.65 and a beta of 0.32. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The firm had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. During the same period in the previous year, the company posted $2.68 EPS. Jazz Pharmaceuticals's quarterly revenue was down .5% compared to the same quarter last year. On average, sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Robert W. Baird decreased their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Piper Sandler restated an "overweight" rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Wall Street Zen lowered shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Finally, Morgan Stanley reduced their target price on shares of Jazz Pharmaceuticals from $166.00 to $165.00 and set an "overweight" rating on the stock in a report on Tuesday, July 22nd. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $181.64.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the sale, the chief executive officer owned 436,973 shares of the company's stock, valued at $47,031,403.99. This trade represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Seamus Mulligan acquired 1,621 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were bought at an average cost of $103.00 per share, for a total transaction of $166,963.00. Following the transaction, the director owned 101,621 shares of the company's stock, valued at $10,466,963. This represents a 1.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 2,500 shares of company stock worth $277,930. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.